Atrial fibrillation in low- and middle-income countries: a narrative review

Abstract Preventing premature non-communicable disease mortality necessitates a thorough review of one of the most important risk factors for stroke, which is atrial fibrillation (AF). The latter and AF-related stroke are still considered to be problems of high-income countries and are frequently overlooked in low- and middle-income countries (LMICs). In this narrative review, we provide an overview of studies that evaluated at least one of the following determinants of AF burden in LMICs: current epidemiology and trends, stroke prevention, health outcomes, and economic burden. Studies focusing on samples close to the general population (including community- and primary care-based samples) indicate sex-specific prevalence rates up to 7.4% in LMICs. Although AF prevalence is still higher in high-income countries than LMICs, the gap in AF burden between these two groups has been reducing in the past three decades. Oral anticoagulant (OAC) therapy for stroke prevention is underused in LMICs, and there are little data on OAC therapy in relation to stroke risk scores, such as CHA2DS2-VASc. Available data also points to higher morbidity and mortality for patient with AF in LMICs than their counterparts in high-income countries. Data on the consequent economic burden in LMICs is scarce, but it is reasonable to consider it will follow the same trend as that observed for health outcomes. Raising the visibility of AF as a public health problem in LMICs is necessary as a first step to providing adequate care for patients with this condition.

[1]  Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). , 2020, European heart journal.

[2]  Jeroen J. Bax,et al.  2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). , 2020, European heart journal.

[3]  M. Abdulkadir,et al.  Appropriate use of anti-thrombotic therapy in patients with atrial fibrillation at single-center experience, Northwest Ethiopia , 2020, BMC Cardiovascular Disorders.

[4]  S. Yusuf,et al.  Global variations in the prevalence, treatment, and impact of atrial fibrillation in a multi-national cohort of 153,152 middle-aged individuals. , 2020, Cardiovascular research.

[5]  Jianhong Wu,et al.  Global, regional, and national prevalence, incidence, mortality, and risk factors for atrial fibrillation, 1990–2017: results from the Global Burden of Disease Study 2017 , 2020, European heart journal. Quality of care & clinical outcomes.

[6]  Manoel Horta Ribeiro,et al.  Evaluation of Mortality in Atrial Fibrillation: Clinical Outcomes in Digital Electrocardiography (CODE) Study , 2020, Global heart.

[7]  M. Di Maio,et al.  Non‐vitamin K vs vitamin K oral anticoagulants in patients aged > 80 year with atrial fibrillation and low body weight , 2020, European journal of clinical investigation.

[8]  K. Jolly,et al.  Clinicians’ views and experiences of prescribing oral anticoagulants for stroke prevention in atrial fibrillation: A qualitative meta-synthesis , 2020, PloS one.

[9]  M. Márquez,et al.  Anticoagulation Therapy by Age and Embolic Risk for Nonvalvular Atrial Fibrillation in Mexico, an Upper-Middle-Income Country: The CARMEN-AF Registry , 2020, Global heart.

[10]  E. Bahiru,et al.  Cardiac arrhythmias in low- and middle-income countries. , 2020, Cardiovascular diagnosis and therapy.

[11]  Dmitri A. Jdanov,et al.  Atrial fibrillation among Russian men and women aged 55 years and older: prevalence, mortality, and associations with biomarkers in a population-based study , 2020, Journal of geriatric cardiology : JGC.

[12]  J. Mardekian,et al.  Terapia de Anticoagulação em Pacientes com Fibrilação Atrial não Valvar em Ambiente de Cuidado de Saúde Privado no Brasil: Um Estudo de Mundo Real , 2020, Arquivos brasileiros de cardiologia.

[13]  S. Kimmel,et al.  Genetic Factors Influencing Warfarin Dose in Black‐African Patients: A Systematic Review and Meta‐Analysis , 2019, Clinical pharmacology and therapeutics.

[14]  R. Kabra,et al.  Racial Differences in Atrial Fibrillation Epidemiology, Management, and Outcomes , 2019, Current Treatment Options in Cardiovascular Medicine.

[15]  Manoel Horta Ribeiro,et al.  Evaluation of mortality in bundle branch block patients from an electronic cohort: Clinical Outcomes in Digital Electrocardiography (CODE) study. , 2019, Journal of electrocardiology.

[16]  G. Lip,et al.  Prevalence of modifiable risk factors and relation to stroke and death in patients with atrial fibrillation: A report from the China atrial fibrillation registry study , 2019, Journal of cardiovascular electrophysiology.

[17]  L. Goldstein,et al.  A Review of the Burden of Atrial Fibrillation: Understanding the Impact of the New Millennium Epidemic across Europe , 2019, EMJ Cardiology.

[18]  Shuang Liu,et al.  Epidemiology of atrial fibrillation in northeast China: a cross-sectional study, 2017–2019 , 2019, Heart.

[19]  R. Tieleman,et al.  Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings , 2019, PloS one.

[20]  R. Tieleman,et al.  Atrial Fibrillation in Africa-An Underreported and Unrecognized Risk Factor for Stroke: A Systematic Review. , 2019, Global heart.

[21]  R. Lopes,et al.  Prevalence of atrial fibrillation and stroke risk assessment based on telemedicine screening tools in a primary healthcare setting. , 2019, European journal of internal medicine.

[22]  G. Lip,et al.  Kerala Atrial Fibrillation Registry: a prospective observational study on clinical characteristics, treatment pattern and outcome of atrial fibrillation in Kerala, India, cohort profile , 2019, BMJ Open.

[23]  Fares Alahdab,et al.  Global, regional, and national burden of stroke, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2019, The Lancet Neurology.

[24]  L. Chen,et al.  Sex and racial differences in cardiovascular disease risk in patients with atrial fibrillation , 2019, bioRxiv.

[25]  K. Pieper,et al.  Stroke prevention in patients from Latin American countries with non‐valvular atrial fibrillation: Insights from the GARFIELD‐AF registry , 2019, Clinical cardiology.

[26]  D. McManus,et al.  Age-and-sex stratified prevalence of atrial fibrillation in rural Western India: Results of SMART-India, a population-based screening study. , 2019, International journal of cardiology.

[27]  E. Tegene,et al.  Prevalence and risk factors for atrial fibrillation and its anticoagulant requirement in adults aged ≥40 in Jimma Town, Southwest Ethiopia: A community based cross-sectional study , 2019, International journal of cardiology. Heart & vasculature.

[28]  S. Lemma,et al.  Mortality among pediatric patients on HIV treatment in sub-Saharan African countries: a systematic review and meta-analysis , 2019, BMC Public Health.

[29]  Haniye Sadat Sajadi,et al.  Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2018, Lancet.

[30]  H. Zhang,et al.  Prevalence of atrial fibrillation in different socioeconomic regions of China and its association with stroke: Results from a national stroke screening survey. , 2018, International journal of cardiology.

[31]  Jeffrey I. Campbell,et al.  Low population prevalence of atrial fibrillation in rural Uganda: A community-based cross-sectional study. , 2018, International journal of cardiology.

[32]  S. Harikrishnan,et al.  Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. , 2018, Lancet.

[33]  M. Trancart,et al.  Economic burden of thromboembolic and hemorrhagic complications in non-valvular atrial fibrillation in Algeria (the ELRAGFA study) , 2018, Journal of medical economics.

[34]  Mehrad Amin Eskandari,et al.  Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry , 2018, Indian heart journal.

[35]  L. Pezzullo,et al.  The Economic Burden of Heart Conditions in Brazil , 2018, Arquivos brasileiros de cardiologia.

[36]  C. Mathers,et al.  Acting on non-communicable diseases in low- and middle-income tropical countries , 2018, Nature.

[37]  A. Bryer,et al.  Poor anticoagulation control in patients taking warfarin at a tertiary and district-level prothrombin clinic in Cape Town, South Africa. , 2018, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[38]  O. D. Del Brutto,et al.  Low prevalence of atrial fibrillation in Amerindians: a population-based study in frequent fish consumers living in rural coastal Ecuador (The Atahualpa Project) , 2018, Aging Clinical and Experimental Research.

[39]  G. Lip,et al.  Increasing trends in hospital care burden of atrial fibrillation in Korea, 2006 through 2015 , 2018, Heart.

[40]  D. Fitzmaurice,et al.  Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation , 2017, BMJ Open.

[41]  G. Bloomfield,et al.  Clinical characteristics and 12-month outcomes of patients with valvular and non-valvular atrial fibrillation in Kenya , 2017, PloS one.

[42]  Li Yang,et al.  Comparing the economic burden of ischemic stroke patients with and without atrial fibrillation: a retrospective study in Beijing, China , 2017, Current medical research and opinion.

[43]  John Stover,et al.  Financing transformative health systems towards achievement of the health Sustainable Development Goals: a model for projected resource needs in 67 low-income and middle-income countries , 2017, The Lancet. Global health.

[44]  F. Rutten,et al.  Predictive performance of the CHA2DS2‐VASc rule in atrial fibrillation: a systematic review and meta‐analysis , 2017, Journal of thrombosis and haemostasis : JTH.

[45]  G. Zhang,et al.  Incidence of atrial fibrillation and its risk prediction model based on a prospective urban Han Chinese cohort , 2017, Journal of Human Hypertension.

[46]  Denis Xavier,et al.  The World Heart Federation Roadmap for Nonvalvular Atrial Fibrillation. , 2017, Global heart.

[47]  A. Banerjee,et al.  Atrial fibrillation: the current epidemic , 2017, Journal of geriatric cardiology : JGC.

[48]  E. Schapkaitz,et al.  Predictors of warfarin dose requirements in South African patients attending an anticoagulation clinic. , 2017, Journal of vascular nursing : official publication of the Society for Peripheral Vascular Nursing.

[49]  Jun Zhu,et al.  Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study , 2016, The Lancet.

[50]  Ying Sun,et al.  CHADS2 score has a better predictive value than CHA2DS2-VASc score in elderly patients with atrial fibrillation , 2016, Clinical interventions in aging.

[51]  K. Yusoff,et al.  Prevalence of atrial fibrillation in the Malaysian communities , 2016, Heart Asia.

[52]  D. Fitzmaurice,et al.  Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF , 2016, European heart journal.

[53]  M. Turakhia,et al.  Aspirin Instead of Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Risk for Stroke. , 2016, Journal of the American College of Cardiology.

[54]  R. Lopes,et al.  Rationale and design of the First Brazilian Cardiovascular Registry of Atrial Fibrillation: The RECALL study. , 2016, American heart journal.

[55]  G. Millogo,et al.  Use of Vitamins K antagonists in non-valvular atrial fibrillation thromboembolic risk prevention in Burkina Faso , 2016, The Pan African medical journal.

[56]  D. Hellenberg,et al.  Profile and anticoagulation outcomes of patients on warfarin therapy in an urban hospital in Cape Town, South Africa , 2016, African journal of primary health care & family medicine.

[57]  Rong Zhao,et al.  Predictive role of CHADS2 and CHA2DS2-VASc scores on stroke and thromboembolism in patients without atrial fibrillation: a meta-analysis , 2016, Annals of medicine.

[58]  S. Chugh,et al.  Prevalence of atrial fibrillation in an urban population in India: the Nagpur pilot study , 2016, Heart Asia.

[59]  W. Wongcharoen,et al.  Prevalence of atrial fibrillation in Thai elderly , 2016, Journal of geriatric cardiology : JGC.

[60]  T. Zou,et al.  [Epidemiological survey of atrial fibrillation among Uygur and Han elderly people in Xinjiang Uygur autonomous region]. , 2015, Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi.

[61]  D. Matchar,et al.  Prevalence and Risk Factors of Atrial Fibrillation in Chinese Elderly: Results from the Chinese Longitudinal Healthy Longevity Survey , 2015, Chinese medical journal.

[62]  G. Lip,et al.  The CHADS2 and CHA2DS2-VASc scores for predicting ischemic stroke among East Asian patients with atrial fibrillation: A systemic review and meta-analysis. , 2015, International journal of cardiology.

[63]  R. Guimaraes,et al.  Clinical Differences between Subtypes of Atrial Fibrillation and Flutter: Cross-Sectional Registry of 407 Patients , 2015, Arquivos brasileiros de cardiologia.

[64]  Yan Li,et al.  The prevalence, incidence, management and risks of atrial fibrillation in an elderly Chinese population: a prospective study , 2015, BMC Cardiovascular Disorders.

[65]  S. Yusuf,et al.  Characteristics, complications, and gaps in evidence-based interventions in rheumatic heart disease: the Global Rheumatic Heart Disease Registry (the REMEDY study). , 2014, European heart journal.

[66]  S. Albayrak,et al.  Predictors of major adverse cardiovascular events; results of population based MELEN study with prospective follow-up. , 2015, European review for medical and pharmacological sciences.

[67]  B. Gersh,et al.  Misperceptions of aspirin efficacy and safety may perpetuate anticoagulant underutilization in atrial fibrillation. , 2015, European heart journal.

[68]  Yingxian Sun,et al.  Prevalence of atrial fibrillation and its risk factors in rural China: a cross-sectional study. , 2015, International journal of cardiology.

[69]  Faisal Rahman,et al.  Global epidemiology of atrial fibrillation , 2014, Nature Reviews Cardiology.

[70]  J. Mould-Quevedo,et al.  Burden of disease from atrial fibrillation in adults from seven countries in Latin America , 2014, International journal of general medicine.

[71]  S. Ocheni,et al.  Utilization of Oral Anticoagulation in a Teaching Hospital in Nigeria , 2014, Annals of medical and health sciences research.

[72]  L. C. Danzmann,et al.  Prevalence of oral anticoagulation in atrial fibrillation , 2014, Clinics.

[73]  C. Siu,et al.  Risk of stroke and intracranial hemorrhage in 9727 Chinese with atrial fibrillation in Hong Kong. , 2014, Heart rhythm.

[74]  R. Jardine,et al.  A survey on the treatment of atrial fibrillation in South Africa. , 2014, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[75]  Jun Zhu,et al.  Risk factors and incidence of stroke and MACE in Chinese atrial fibrillation patients presenting to emergency departments: a national wide database analysis. , 2014, International journal of cardiology.

[76]  B. Monz,et al.  Treatment Costs of Stroke Related to Nonvalvular Atrial Fibrillation Patients in India-A Multicenter Observational Study. , 2014, Value in health regional issues.

[77]  George A Mensah,et al.  Global burden of atrial fibrillation in developed and developing nations. , 2014, Global heart.

[78]  C. Chiang,et al.  Use of antithrombotics in atrial fibrillation in Africa, Europe, Asia and South America: insights from the International RealiseAF Survey. , 2014, Archives of cardiovascular diseases.

[79]  I. V. Van Gelder,et al.  Variations in Cause and Management of Atrial Fibrillation in a Prospective Registry of 15 400 Emergency Department Patients in 46 Countries: The RE-LY Atrial Fibrillation Registry , 2014, Circulation.

[80]  Yutao Guo,et al.  Validation of contemporary stroke and bleeding risk stratification scores in non-anticoagulated Chinese patients with atrial fibrillation. , 2013, International journal of cardiology.

[81]  Hong-yan Lu,et al.  CHADS2 versus CHA2DS2-VASc score in assessing the stroke and thromboembolism risk stratification in patients with atrial fibrillation: a systematic review and meta-analysis , 2013, Journal of geriatric cardiology : JGC.

[82]  Y. Li,et al.  Prevalence of atrial fibrillation in China and its risk factors. , 2013, Biomedical and environmental sciences : BES.

[83]  Yusuke Nakamura,et al.  Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study , 2013, The Lancet.

[84]  M. Zubaid,et al.  Stroke prevention in atrial fibrillation--an Asian stroke perspective. , 2013, Heart rhythm.

[85]  Shanlian Hu,et al.  Economic Burden of Individual Suffering from Atrial Fibrillation-Related Stroke in China. , 2013, Value in health regional issues.

[86]  G. Yonga,et al.  Clinical characteristics and outcomes of atrial fibrillation and flutter at the Aga Khan University Hospital, Nairobi , 2013, Cardiovascular journal of Africa.

[87]  O. Osi-Ogbu,et al.  Stroke risk factors, subtypes, and 30-day case fatality in Abuja, Nigeria , 2013, Nigerian medical journal : journal of the Nigeria Medical Association.

[88]  P. Fasinu,et al.  Comparative evaluation of warfarin utilisation in two primary healthcare clinics in the Cape Town area , 2013, Cardiovascular journal of Africa.

[89]  I. Sabir,et al.  Antithrombotic therapy in atrial fibrillation: aspirin is rarely the right choice , 2013, Postgraduate Medical Journal.

[90]  Gregory Y H Lip,et al.  The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe. , 2012, Chest.

[91]  K. Sliwa,et al.  The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries. , 2012, Archives of internal medicine.

[92]  Zhi-qiang Liu,et al.  [The prevalence and distributing feature of atrial fibrillation in Xinjiang Uygur Autonomous Region Kazaks adult population]. , 2012, Zhonghua nei ke za zhi.

[93]  R. Walker,et al.  Strikingly Low Prevalence of Atrial Fibrillation in Elderly Tanzanians , 2012, Journal of the American Geriatrics Society.

[94]  C. Cirenza,et al.  Estudo transversal das estratégias de tratamento clínico na fibrilação atrial , 2012 .

[95]  J. Piccini,et al.  International variation in use of oral anticoagulation among heart failure patients with atrial fibrillation. , 2012, American heart journal.

[96]  T. Lam,et al.  Atrial fibrillation and obesity among older Chinese: the Guangzhou Biobank Cohort Study. , 2011, International journal of cardiology.

[97]  K. Sliwa,et al.  Predisposing factors and incidence of newly diagnosed atrial fibrillation in an urban African community: insights from the Heart of Soweto Study , 2010, Heart.

[98]  S. Yusuf,et al.  Newly identified events in the RE-LY trial. , 2010, The New England journal of medicine.

[99]  G. Lip,et al.  Underuse of oral anticoagulants in atrial fibrillation: a systematic review. , 2010, The American journal of medicine.

[100]  Jeroen J. Bax,et al.  Prognosis of atrial fibrillation in patients with symptomatic peripheral arterial disease: data from the REduction of Atherothrombosis for Continued Health (REACH) Registry. , 2010, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[101]  V. Howard,et al.  Racial Disparities in Awareness and Treatment of Atrial Fibrillation: The REasons for Geographic and Racial Differences in Stroke (REGARDS) Study , 2010, Stroke.

[102]  P. Urban,et al.  Atrial fibrillation in Africa: clinical characteristics, prognosis, and adherence to guidelines in Cameroon. , 2010, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[103]  E. Benjamin,et al.  Association of obesity and atrial fibrillation among middle-aged and elderly Chinese , 2009, International Journal of Obesity.

[104]  K. Sliwa,et al.  Predominance of Heart Failure in the Heart of Soweto Study Cohort: Emerging Challenges for Urban African Communities , 2008, Circulation.

[105]  D. Hu,et al.  An Epidemiological Study on the Prevalence of Atrial Fibrillation in the Chinese Population of Mainland China , 2008, Journal of epidemiology.

[106]  G. Can,et al.  [Incidence, prevalence, and mortality estimates for chronic atrial fibrillation in Turkish adults]. , 2008, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[107]  O. O’Donnell,et al.  Access to health care in developing countries: breaking down demand side barriers. , 2007, Cadernos de saude publica.

[108]  M. Connor,et al.  The South African stroke risk in general practice study. , 2005, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[109]  G. Lip,et al.  Admissions with atrial fibrillation in a multiracial population in Kuala Lumpur, Malaysia. , 2003, International journal of cardiology.

[110]  E. Darzé,et al.  Trends and Predictors of Oral Anticoagulation in Patients with Atrial Fibrillation: A Serial Cross-Sectional Study from 2011 to 2016 , 2019, International Journal of Cardiovascular Sciences.

[111]  A. Nickfarjam,et al.  Registry Data Coordinator (RDC): a Proper Accessible Strategy for Improving Road Traffic Injury (RTI) Hospital Based Trauma Registry Systems in Developing Countries and Low Income Countries , 2018, Acta informatica medica : AIM : journal of the Society for Medical Informatics of Bosnia & Herzegovina : casopis Drustva za medicinsku informatiku BiH.

[112]  M. Márquez,et al.  [Design of an atrial fibrillation and embolic risk registry in Mexico: CARMEN-AF]. , 2017, Archivos de cardiologia de Mexico.

[113]  M. Márquez,et al.  Diseño de un registro de fibrilación auricular y riesgo embólico en México: CARMEN-AF , 2017 .

[114]  S. Ofori,et al.  Atrial fibrillation: An analysis of etiology and management pattern in a tertiary hospital in Port-harcourt, southern Nigeria , 2015 .

[115]  I. Germain,et al.  Non Valvular Atrial Fibrillation Related Ischaemic Stroke at the Teaching Hospital of Yalgado Ouédraogo, Burkina Faso , 2015 .

[116]  Hao Wang,et al.  Prevalence, incidence, and lifetime risk of atrial fibrillation in China: new insights into the global burden of atrial fibrillation. , 2015, Chest.

[117]  I. Benseñor,et al.  Atrial fibrillation and dementia: results from the Sao Paulo ageing & health study. , 2012, Arquivos brasileiros de cardiologia.

[118]  M. Márquez,et al.  [Design of a multicenter registry to evaluate rhythm versus rate control in atrial fibrillation: Atrial Fibrillation Mexican Registry (ReMeFA)]. , 2011, Archivos de cardiologia de Mexico.

[119]  P. Iturralde-Torres,et al.  Diseño de un registro multicéntrico para evaluar control de ritmo contra control de la frecuencia en fibrilación auricular: Registro Mexicano de Fibrilación Auricular (ReMeFA) , 2011 .

[120]  F. Habibzadeh,et al.  Prevalence of atrial fibrillation in a primary health care centre in Fars Province, Islamic Republic of Iran. , 2004, Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit.